{"id":82468,"date":"2025-10-20T10:37:04","date_gmt":"2025-10-20T10:37:04","guid":{"rendered":"https:\/\/www.cofb.org\/?p=82468"},"modified":"2025-10-23T10:37:37","modified_gmt":"2025-10-23T10:37:37","slug":"quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","title":{"rendered":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?"},"content":{"rendered":"\n

El passat 8 d\u2019octubre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB)<\/strong> va acollir la jornada formativa \u201cNoves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur<\/strong>\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica<\/strong> (SCFC) i el patrocini de Johnson&Johnson<\/a>. La sessi\u00f3 va comptar amb la participaci\u00f3 de Natalia Picola<\/strong>, ur\u00f2loga adjunta al Servei d\u2019Urologia de l\u2019Hospital Universitari de Bellvitge i membre de l\u2019equip m\u00e8dic d\u2019Urocl\u00ednica; Ge\u00f2rgia Anguera<\/strong>, onc\u00f2loga m\u00e8dica especialista en genitourinari, adjunta al Servei d\u2019Oncologia M\u00e8dica de l\u2019Hospital de la Santa Creu i Sant Pau; In\u00e9s Monge<\/strong>, farmac\u00e8utica del Servei de Farm\u00e0cia de l\u2019Hospital Cl\u00ednic de Barcelona; i Enric Lizano<\/strong>, farmac\u00e8utic i t\u00e8cnic de la Divisi\u00f3 d\u2019\u00fas racional del medicament de l\u2019\u00c0rea del Medicament del Servei Catal\u00e0 de la Salut. David Conde<\/strong>, vocal d\u2019Hospitals del COFB, va moderar la sessi\u00f3.<\/p>\n\n\n\n

Els objectius de la formaci\u00f3<\/strong>, adre\u00e7ada a farmac\u00e8utics\/ques d\u2019hospital i d\u2019atenci\u00f3 prim\u00e0ria, van ser revisar la fisiopatologia i les dianes terap\u00e8utiques<\/strong> del c\u00e0ncer de pr\u00f2stata i de bufeta<\/strong>, actualitzar la gesti\u00f3 i el tractament<\/strong> del c\u00e0ncer de pr\u00f2stata, con\u00e8ixer aspectes d’atenci\u00f3 farmac\u00e8utica<\/strong> relacionats amb la dispensaci\u00f3 i el seguiment<\/strong> i reflexionar sobre els mecanismes per a la incorporaci\u00f3 de la innovaci\u00f3<\/strong> en el sistema sanitari<\/strong>.<\/p>\n\n\n\n

Durant la presentaci\u00f3, David Conde<\/strong> va explicar la necessitat de \u201cfer un rep\u00e0s general de la patologia<\/strong> i tenir unes pinzellades del que vindr\u00e0 a futur. La innovaci\u00f3 arriba molt r\u00e0pidament en aquests c\u00e0ncers i ha d\u2019arribar al pacient, ja que s\u2019est\u00e0 aconseguint canviar l\u2019evoluci\u00f3 de la malaltia<\/strong>\u201d. A m\u00e9s, va afegir que la participaci\u00f3 de la farm\u00e0cia en aquest escenari \u201ctamb\u00e9 \u00e9s important, perqu\u00e8 es pot aconseguir no nom\u00e9s un impacte pel pacient<\/strong>, sin\u00f3 que tamb\u00e9 per l\u2019economia<\/strong>\u201d.<\/p>\n\n\n\n

Abast del c\u00e0ncer de pr\u00f2stata en la poblaci\u00f3 masculina<\/h2>\n\n\n\n

En la primera presentaci\u00f3, Natalia Picola<\/strong> la va arrancar recordant que el c\u00e0ncer de pr\u00f2stata<\/strong> \u201c\u00e9s la segona neopl\u00e0sia m\u00e9s diagnosticada en l\u2019home<\/strong> en l\u2019\u00e0mbit mundial i la primera a partir dels 55 anys. Al llarg del 2020 es van detectar 1,4 milions de nous diagn\u00f2stics<\/strong> a escala mundial i, a Espanya, \u00e9s la tercera causa de mort per c\u00e0ncer entre els homes\u201d.<\/p>\n\n\n\n

\"Natalia<\/a>
Natalia Picola, en un moment de la seva presentaci\u00f3.<\/figcaption><\/figure>\n\n\n\n

Enfront aquesta situaci\u00f3, Picola va afirmar que la majoria dels pacients<\/strong> que pateixen aquesta malaltia \u201cs\u00f3n diagnosticats en fases inicials<\/strong> i amb el c\u00e0ncer molt localitzat<\/strong>. Existeixen nombrosos programes de detecci\u00f3 individual preco\u00e7, i un dels grans canvis<\/strong> en aquest sentit que ja s\u2019est\u00e0 consolidant \u00e9s la imatge molecular<\/strong>\u201d.<\/p>\n\n\n\n

Impacte del carcinoma uroterial a Espanya<\/h2>\n\n\n\n

Georgia Anguera<\/strong> va iniciar la seva exposici\u00f3 tenint molt present l\u2019impacte del carcinoma urotelial<\/strong> a Espanya: \u201cEs tracta del cinqu\u00e8 c\u00e0ncer m\u00e9s diagnosticat<\/strong> al pa\u00eds durant el 2025. Entre els factors de risc<\/strong> hi ha el tabac, l\u2019exposici\u00f3 a t\u00f2xics laborals<\/strong> com les amines arom\u00e0tiques<\/strong> i l\u2019esquistosomiasi<\/strong>\u201d.<\/p>\n\n\n\n

Pel que fa a la presentaci\u00f3 cl\u00ednica de la tipologia<\/strong> m\u00e9s comuna en el c\u00e0ncer de bufeta, \u201cen el 80% dels casos els pacients pateixen hemat\u00faria<\/strong> i s\u00edmptomes urinaris irritatius<\/strong> com la dis\u00faria\u201d.<\/p>\n\n\n\n

\"Georgia<\/a>
Georgia Anguera va explicar els aven\u00e7os significatius en els \u00faltims anys lligats al carcinoma urotelial.<\/figcaption><\/figure>\n\n\n\n

Anguera va finalitzar la seva pon\u00e8ncia afirmant que hi ha aven\u00e7os cient\u00edfics significatius<\/strong> en els \u00faltims anys lligats al carcinoma urotelial: \u201cPel que fa a la malaltia localitzada<\/strong>, el tractament actual \u00e9s quimioter\u00e0pia<\/strong> basada en cisplat\u00ed<\/strong>, cistectomia<\/strong> i Nivolumab<\/strong>, mentre que al carcinoma metast\u00e0tic<\/strong>, existeix la quimioter\u00e0pia basada en plat\u00ed <\/strong>i la recent aprovaci\u00f3 d\u2019Erdafitinib<\/strong>, la primera droga amb diana terap\u00e8utica en carcinoma urotelial\u201d.<\/p>\n\n\n\n

Estrat\u00e8gies terap\u00e8utiques en c\u00e0ncer de pr\u00f2stata i bufeta<\/h2>\n\n\n\n

\u201cL\u2019arsenal terap\u00e8utic disponible<\/strong> en c\u00e0ncer de pr\u00f2stata<\/strong> \u00e9s m\u00e9s ampli que en el c\u00e0ncer de bufeta<\/strong>\u201d, va afirmar In\u00e9s Monge durant la tercera part de la confer\u00e8ncia. En aquest context, l\u2019elecci\u00f3 del tractament en el cas de la pr\u00f2stata s\u2019ha de prendre \u201ctenint en compte el perfil de seguretat del f\u00e0rmac<\/strong> i les condicions cl\u00edniques del pacient<\/strong>, incloent-hi comorbiditats i polifarm\u00e0cia associada<\/strong>\u201d.<\/p>\n\n\n\n

\"Els<\/a>
Els tractaments relacionats amb el c\u00e0ncer de bufeta van ser descrits per In\u00e9s Monge.<\/figcaption><\/figure>\n\n\n\n

Pel que fa als tractaments relacionats amb el c\u00e0ncer de bufeta<\/strong>, \u201cen cas que no es localitzi a un m\u00fascul-invasiu<\/strong>, es dur\u00e0 a terme un tractament intravesical. Si es troba a un m\u00fascul invasiu, s\u2019ha de realitzar quimioter\u00e0pia<\/strong>, cistectomia radical<\/strong> o immunoter\u00e0pia<\/strong>\u201d. Finalment, si hi ha met\u00e0stasis, \u201ces dur\u00e0 a terme quimioter\u00e0pia, immunoter\u00e0pia o ter\u00e0pies dirigides\u201d.<\/p>\n\n\n\n

En l\u2019\u00e0mbit d\u2019estrat\u00e8gies terap\u00e8utiques lligades a aquest c\u00e0ncer<\/strong>, Monge va indicar que \u201cs\u2019ha de donar rellev\u00e0ncia a la vigil\u00e0ncia activa, la cirurgia, la radioter\u00e0pia i l\u2019hormonoter\u00e0pia\u201d.<\/p>\n\n\n\n

M\u00e9s assajos i evid\u00e8ncia cient\u00edfica dins el sistema sanitari<\/h2>\n\n\n\n

Amb relaci\u00f3 a les tend\u00e8ncies de futur<\/strong> per a la incorporaci\u00f3 de la innovaci\u00f3 en aquests dos c\u00e0ncers dins el sistema sanitari<\/strong>, Enric Lizano <\/strong>va afirmar que, a Espanya, \u201cexisteix una clara prefer\u00e8ncia a externalitzar la innovaci\u00f3. A m\u00e9s, les petites mol\u00e8cules<\/strong> encara protagonitzen m\u00e9s de la meitat dels acords<\/strong> per la seva simplicitat i cost, i l\u2019oncologia segueix liderant el 40% dels acords<\/strong> que es duen a terme\u201d.<\/p>\n\n\n\n

\"Les
Les tend\u00e8ncies de futur per a la incorporaci\u00f3 de la innovaci\u00f3 en ambd\u00f3s c\u00e0ncers va anar a c\u00e0rrec d’Enric Lizano.<\/figcaption><\/figure>\n\n\n\n

A l\u2019hora d\u2019afrontar els reptes actuals i de futur<\/strong> contra aquests dos c\u00e0ncers, \u201c\u00e9s necessari el desenvolupament de nous marcs<\/strong>, dissenyar nous assajos cl\u00ednics<\/strong> que proporcionin claredat, m\u00e9s coordinaci\u00f3 entre laboratoris<\/strong> i millorar la gesti\u00f3 i l\u2019enfocament en indicacions espec\u00edfiques<\/strong>\u201d.<\/p>\n\n\n\n

Com a conclusi\u00f3 final, Lizano va defensar que, si es vol que la innovaci\u00f3 contra aquests c\u00e0ncers arribi a Espanya, \u201cs\u2019han d\u2019incrementar les novetats<\/strong> i sumar m\u00e9s evid\u00e8ncia cient\u00edfica<\/strong>, establir mesures d\u2019acc\u00e9s gestionat com a eines per reduir la pressi\u00f3<\/strong> i, finalment, la necessitat de focalitzar-se en el valor<\/strong>, l\u2019efici\u00e8ncia<\/strong> i els pacients<\/strong>\u201d.<\/p>\n\n\n\n

Amb el patrocini de:<\/strong><\/p>\n\n\n\n

\"\"<\/a><\/figure>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

El passat 8 d\u2019octubre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la jornada formativa \u201cNoves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) i el patrocini de Johnson&Johnson. La sessi\u00f3 va comptar amb la participaci\u00f3 de Natalia […]<\/p>\n","protected":false},"author":10,"featured_media":82489,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[23,57],"tags":[3070,723,975,18,19,69,70,44,724],"class_list":["post-82468","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-destacats","category-mon-collegial","tag-bufeta","tag-cancer","tag-cancer-de-prostata","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-farmacia-comunitaria","tag-formacio","tag-malaltia","tag-oncologia"],"yoast_head":"\nQuines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El COFB acull la jornada "Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur", amb el patrocini de Johnson&Johnson\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cofb.org\/ca\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El COFB acull la jornada "Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur", amb el patrocini de Johnson&Johnson\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cofb.org\/ca\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T10:37:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-23T10:37:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Xavier Magraner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Xavier Magraner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\"},\"author\":{\"name\":\"Xavier Magraner\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\"},\"headline\":\"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?\",\"datePublished\":\"2025-10-20T10:37:04+00:00\",\"dateModified\":\"2025-10-23T10:37:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\"},\"wordCount\":1112,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\",\"keywords\":[\"bufeta\",\"c\u00e0ncer\",\"c\u00e0ncer de pr\u00f2stata\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"farm\u00e0cia comunit\u00e0ria\",\"Formaci\u00f3\",\"malaltia\",\"oncologia\"],\"articleSection\":[\"Destacats\",\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\",\"url\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\",\"name\":\"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\",\"datePublished\":\"2025-10-20T10:37:04+00:00\",\"dateModified\":\"2025-10-23T10:37:37+00:00\",\"description\":\"El COFB acull la jornada \\\"Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\\\", amb el patrocini de Johnson&Johnson\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg\",\"width\":2560,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4\",\"name\":\"Xavier Magraner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g\",\"caption\":\"Xavier Magraner\"},\"url\":\"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El COFB acull la jornada \"Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\", amb el patrocini de Johnson&Johnson","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cofb.org\/ca\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","og_locale":"ca_ES","og_type":"article","og_title":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El COFB acull la jornada \"Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\", amb el patrocini de Johnson&Johnson","og_url":"https:\/\/www.cofb.org\/ca\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2025-10-20T10:37:04+00:00","article_modified_time":"2025-10-23T10:37:37+00:00","og_image":[{"width":2560,"height":1440,"url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","type":"image\/jpeg"}],"author":"Xavier Magraner","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"Xavier Magraner","Temps estimat de lectura":"7 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#article","isPartOf":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/"},"author":{"name":"Xavier Magraner","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4"},"headline":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?","datePublished":"2025-10-20T10:37:04+00:00","dateModified":"2025-10-23T10:37:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/"},"wordCount":1112,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","keywords":["bufeta","c\u00e0ncer","c\u00e0ncer de pr\u00f2stata","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","farm\u00e0cia comunit\u00e0ria","Formaci\u00f3","malaltia","oncologia"],"articleSection":["Destacats","M\u00f3n col\u00b7legial"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","url":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/","name":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage"},"image":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","datePublished":"2025-10-20T10:37:04+00:00","dateModified":"2025-10-23T10:37:37+00:00","description":"El COFB acull la jornada \"Noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\", amb el patrocini de Johnson&Johnson","breadcrumb":{"@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#primaryimage","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg","width":2560,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/www.cofb.org\/2025\/10\/20\/quines-son-les-noves-estrategies-en-cancer-de-prostata-i-bufeta\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Quines s\u00f3n les noves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta?"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/e46d741cfb92c985a083d163d8270ae4","name":"Xavier Magraner","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa0d1d4df59f71f88eebd5796c5388ff41c58d83c5301eb6e1d65646a289c37d?s=96&d=mm&r=g","caption":"Xavier Magraner"},"url":"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-scaled.jpg",2560,1440,false],"thumbnail":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-150x150.jpg",150,150,true],"medium":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-300x169.jpg",300,169,true],"medium_large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-768x432.jpg",768,432,true],"large":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-1024x576.jpg",1024,576,true],"1536x1536":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-1536x864.jpg",1536,864,true],"2048x2048":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-2048x1152.jpg",2048,1152,true],"trp-custom-language-flag":["https:\/\/www.cofb.org\/wp-content\/uploads\/2025\/10\/COFB_CANCER_PROSTATA_BUFETA_16102025_1-1-18x10.jpg",18,10,true]},"uagb_author_info":{"display_name":"Xavier Magraner","author_link":"https:\/\/www.cofb.org\/ca\/author\/xmagraner\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 8 d\u2019octubre, el Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) va acollir la jornada formativa \u201cNoves estrat\u00e8gies en c\u00e0ncer de pr\u00f2stata i bufeta: present i futur\u201d, amb la col\u00b7laboraci\u00f3 de la Societat Catalana de Farm\u00e0cia Cl\u00ednica (SCFC) i el patrocini de Johnson&Johnson. La sessi\u00f3 va comptar amb la participaci\u00f3 de Natalia […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/82468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=82468"}],"version-history":[{"count":14,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/82468\/revisions"}],"predecessor-version":[{"id":82573,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/82468\/revisions\/82573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media\/82489"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=82468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=82468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=82468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}